Semaglutide vs Empagliflozin Head-to-Head in Uncontrolled Type 2 Diabetes
Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
Quick Facts
What This Study Found
Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
Key Numbers
18 months of follow-up. Compared semaglutide (GLP-1 RA) vs. empagliflozin (SGLT2 inhibitor). Specific outcome data not detailed in abstract.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profi
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).
- Published In:
- Cureus, 17(5), e83416 (2025)
- Authors:
- Aristizabal-Colorado, David, Vernaza Trujillo, David Alexander, Sierra Castillo, Santiago, Rivera Martinez, Wilfredo Antonio, Badiel, Marisol, Abreu Lomba, Alin
- Database ID:
- RPEP-09976
Evidence Hierarchy
Frequently Asked Questions
What does this mean?
Direct comparison of semaglutide and empagliflozin in uncontrolled T2D found distinct efficacy profiles for blood sugar, weight, and cardiometabolic outcomes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09976APA
Aristizabal-Colorado, David; Vernaza Trujillo, David Alexander; Sierra Castillo, Santiago; Rivera Martinez, Wilfredo Antonio; Badiel, Marisol; Abreu Lomba, Alin. (2025). Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).. Cureus, 17(5), e83416. https://doi.org/10.7759/cureus.83416
MLA
Aristizabal-Colorado, David, et al. "Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diabetes: A Cohort Study With 18 Months of Follow-Up (SEMPA18).." Cureus, 2025. https://doi.org/10.7759/cureus.83416
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide Versus Empagliflozin in Uncontrolled Type 2 Diab..." RPEP-09976. Retrieved from https://rethinkpeptides.com/research/aristizabal-colorado-2025-semaglutide-versus-empagliflozin-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.